Press Release (ePRNews.com) - MUNICH - Sep 10, 2018 - Definiens AG, the tissue phenomics company, focused on the development and application of tissue based biomedical digital image analysis, data visualization, data mining solutions and data analysis, today announced that it has entered into a multi-year digital partnership agreement with Merck KGaA, the vibrant science and technology company, to support Merck’s exploratory and clinical development programs using Definiens TissuePhenomics ™ solutions for quantification of biomarkers including immuno-profiling.
“This partnership agreement is a testament to Definiens ability to transform tissue image data into valuable insights using our proprietary data mining methods for biomarker discovery,“ said Oliver Lehner, Definiens VP Business Development and Partnering.
Under the agreement, the healthcare business sector of Merck will use the Definiens novel web-based collaboration software platform that enables Definiens customers to upload, access, explore and share data and will benefit from a dedicated team to maximize synergies between its projects. The partnership with Definiens will foster digital transformation in R&D and support Merck in taking informed decisions with regard to its immuno-oncology product development portfolio based on high quality tissue diagnostics and biomarker data.
Improving patient lives by unlocking the tissue phenome.
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs in immuno-oncology by helping pharmaceutical researchers better leverage tissue-based information through Definiens Tissue Phenomics® – technology. Our expertise accelerates and deepens understanding of disease biology and immune system mechanisms and allows to bring multi-omics data into a cancer-relevant context, which facilitates the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique and actionable patient profiles through harmonized biomarkers for an individualized standard of care, where patients experience fewer side effects and live longer. Definiens’ proven technology has been used in thousands of projects, yielding results that have accelerated drug development and produced over 1000 peer-reviewed publications.
Definiens is a member of the AstraZeneca group providing products and services to companies across the life sciences sector, including MedImmune, the global biologics research and development arm of AstraZeneca.
Media Contact: Adrian Arechiga; firstname.lastname@example.org